Antioxidants block proteasome inhibitor function in endometrial carcinoma cells

Anti-Cancer Drugs

Volumn 19, Issue 2, 2008, Pages 115-124

  Llobet, David ^a   Eritja, Nuria ^a   Encinas, Mario ^a   Sorolla, Anabel ^a   Yeramian, Andree ^a   Schoenenberger, Joan Antoni ^a   Llombart Cussac, Antonio ^a   Marti, Rosa M ^a   Matias Guiu, Xavier ^a   Dolcet, Xavier ^a,b  

^a UNIVERSITY OF LLEIDA   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Antioxidant; Apoptosis; Endometrial carcinoma; Proteasome inhibitor

Indexed keywords

ALDEHYDE; ALLN; ANTIOXIDANT; ASCORBIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; EPOXOMICIN; EPOXYKETONE; NORPHENAZONE; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; TIRON; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL DEATH; CYTOTOXICITY; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIOXIDANTS; ANTIPYRINE; APOPTOSIS; ASCORBIC ACID; BLOTTING, WESTERN; BORONIC ACIDS; BUTYLATED HYDROXYANISOLE; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; ERGOTHIONEINE; FEMALE; HUMANS; LEUPEPTINS; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; UBIQUITIN; VITAMIN E; VITAMINS;

EID: 37849018320     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f24031     Document Type: Article

References (28)

1. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-16647.
2. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28:607-612.
3. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
4. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101:2377-2380.
5. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000.
6. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57:33-47.
7. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5:2638-2645.
8. 2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9:1145-1154.
9. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61:3535-3540.
10. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, et al. The proteasome inhibitor PS-341 overcomes trail resistance in bax and caspase 9-negative or bcl-xl overexpressing cells. Oncogene 2003; 22:4953-4963.
11. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6:3719-3728.
12. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005; 65:11658-11666.
13. Dolcet X, Llobet D, Encinas M, Pallares J, Cabero A, Schoenenberger JA, et al. Proteasome inhibitors induce death but activate NF-kappa B on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006; 281:22118-22130.
14. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21:245-273.
15. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278:33714-33723.
16. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24:9695-9704.
17. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of Ros and Noxa activation independent of p53 status. Blood 2006; 107:257-264.
18. Fernandez Y, Miller TP, Denoyelle C, Esteban JA, Tang WH, Bengston AL, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem 2006; 281:1107-1118.
19. Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S, et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006; 12:273-280.
20. Fribley A, Wang CY. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 2006; 5:745-748.
21. Catley L, Anderson KC. Velcade and vitamin C: too much of a good thing? Clin Cancer Res 2006; 12:3-4.
22. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006; 281:11923-11932.
23. Tsujita K, Shimomura H, Kawano H, Hokamaki J, Fukuda M, Yamashita T, et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 2004; 94:481-484.
24. Tsujita K, Shimomura H, Kaikita K, Kawano H, Hokamaki J, Nagayoshi Y, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J 2006; 70:832-837.
25. Dohi K, Satoh K, Mihara Y, Nakamura S, Miyake Y, Ohtaki H, et al. Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury. J Neurotrauma 2006; 23:1591-1599.
26. Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006; 12:9-20.
27. Kokura S, Yoshida N, Sakamoto N, Ishikawa T, Takagi T, Higashihara H, et al. The radical scavenger edaravone enhances the antitumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappa B. Cancer Lett 2005; 229:223-233.
28. Suzuki R, Gopalrao RK, Maeda H, Rao P, Yamamoto M, Xing Y, et al. MCI-186 inhibits tumor growth through suppression of EGFR phosphorylation and cell cycle arrest. Anticancer Res 2005; 25: 1131-1138.